Table 1.

Patient and treatment characteristics.

Eyes (patients), n	164 (134)
Mean age (range), years	75.9 (56–92)
Women, n (%)	75 (56.0)
Angiographic classification, n (%)
Occult with no classic	95 (57.9)
Predominantly classic	37 (22.6)
Minimally classic	11 (6.7)
Polypoidal choroidal vasculopathy	14 (8.5)
Retinal angiomatous proliferation	7 (4.3)
Eyes refractory to bevacizumab, n (%)	101 (61.6)
Eyes on treatment with ranibizumab, n (%)	63 (38.4)
Mean time on therapy ± SD, months
Prior to switch	28.5 ± 19.1
Aflibercept	29.9 ± 9.0